T1	MultiCitation 984 985	6
T13	Span 703 990	Hallmarks of these tumors include a high enrichment for a CD44+/CD24-/low TIC signature, a downregulation of cell junction proteins such as cadherins and claudins, an enrichment in mesenchymal markers, high lymphocyte infiltrations, and high phenotypic resistance to chemotherapy [6,11].
R2	Context Target:T1 Context:T13	
